Neva Sgr continues to invest and plans to launch a new Fund

Neva Sgr has successfully completed the €250 million fundraising for its Neva First Fund and announces the launch of a new, larger Fund for 2024, capable of also attracting new talent from abroad.

Neva Sgr is an Intesa Sanpaolo Group company wholly owned by Intesa Sanpaolo Innovation Center and, since August 2020, has invested in 26 companies for an allocated total of approximately €150 million.

Among the Neva First Fund's largest investments are those in: R3, Yolo, MatiPay, D-Orbit, iwoca, Diamanti, vFunction, blubrake, Jumple, TechStars, Rocket Internet Capital Partner I & II, Endeavour Catalyst III, Classiq, Seed-X, Cyberint, Coro, and lastly, Tr1X.

Furthermore, Intesa Sanpaolo Innovation Center, in collaboration with Neva Sgr, will launch the SEI Fund – Innovation Ecosystem Development – to support the growth of the Italian innovation ecosystem with an initial endowment of €15 million, fully subscribed by Intesa Sanpaolo.

These announcements were made today at the event "Venture Capital: protagonists, growth and projects of Neva Sgr" organised in Turin by Neva Sgr, which hosted over 500 attendees, including venture capitalists, institutional investors, private clients, entrepreneurs and start-ups.

At the panel discussion "Entrepreneurs' Speak Out" the contributions of five start-up founders well represented the composition of Neva's portfolio:

• Giorgio Tinacci, founder and CEO of Casavo - Europe's first instant buyer for on-line home sales
• Luca Rossettini, founder and CEO of D-Orbit - Italian company and world leader in logistics for the space economy
• David Rutter, founder and CEO of the US-based R3 - a leading company in blockchain - distributed ledger technology
• Dror Liwer, founder of the Israeli Coro - artificial intelligence-based cybersecurity for SMEs
• Maria Grazia Roncarolo, an Italian researcher recognised as one of the world's leading authorities in the field of gene therapies, founder of Tr1X - universal cell therapies for autoimmune diseases.